



Targeted and Combination Therapy: Multi-Omic Approaches and Patient-Derived Models for Ultra-Precise Cancer Therapy

Guest Editor:

Dr. Hatem E. Sabaawy

Rutgers Cancer Institute of New
Jersey

Deadline for manuscript
submissions:

closed (31 July 2022)

Message from the Guest Editor

Dear Colleagues,

This Special Issue will focus on presenting targeted therapy and combination therapy approaches to cancers such as glioblastoma, advanced prostate cancer, and other advanced cancers. This would include genomic, epigenetic, and proteomic profiling of patient tissues, identification of targetable pathways, preclinical studies using patient-derived cells (PDCs), spheres or spheroids (PDSs), organoids (PDOs), and xenografts (PDXs), and early phase or translational studies. The emphasis will be on approaches to identifying intratumor heterogeneity, predicting therapeutic resistance, evolving treatment against tumor-driving clones for personalized therapy, and, at each stage of the disease, achieving ultimate therapeutic responses with ultra-precise therapy.

Dr. Hatem E. Sabaawy

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)